Treatment of Patients With COVID-19 With Convalescent Plasma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

129 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2022-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The COVID-19 pandemic has been spreading continuously, and in Brazil, until May 31, 2020, there have been more than 450.000 cases with more than 28.000 deaths, with daily increases. The present study proposes to evaluate the efficacy and safety of convalescent plasma in treatment of severe cases of COVID-19 in a multicenter, randomized, open-label and controlled study

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support

NCT04528368

COVID-19

UNKNOWN PHASE2

COVID-19 Convalescent Plasma Therapy

NCT04747158

SARS-CoV-2 Infection COVID-19 Infection

COMPLETED PHASE2/PHASE3

Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection

NCT04408209

COVID-19 Infection

COMPLETED NA

Convalescent Plasma for Severe COVID-19 Patients

NCT04547660

Covid19

COMPLETED PHASE3

Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease

NCT04542967

Severe COVID-19 Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients will be randomized 1:1:1 into 3 treatment groups: A- standard (control); B- standard and convalescent plasma in a volume of 200ml (150-300ml); C- standard and convalescent plasma in a volume of 400ml (300-600ml). The Bayesian multi-arm and multi-stage model will be used, which will allow an interim analysis after the inclusion of 30 patients, with repeated interim analyses for every 30 additional patients. With this, we expect to define not only the efficacy of convalescent plasma, but also the volume of plasma needed if efficacy is proven. The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1:1:1 into 3 treatment groups: A- standard (control); B- standard and convalescent plasma in a volume of 200ml (150-300ml); C- standard and convalescent plasma in a volume of 400ml (300-600ml)

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Participants will receive the standard of care treatment

Group Type SHAM_COMPARATOR

convalescent plasma

Intervention Type BIOLOGICAL

The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.

Group B

Participants will receive the standard treatment and convalescent plasma in a volume of 200ml (150-300ml)

Group Type ACTIVE_COMPARATOR

convalescent plasma

Intervention Type BIOLOGICAL

The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.

Group C

Participants will receive the standard treatment and convalescent plasma in a volume of 400ml (300-600ml)

Group Type ACTIVE_COMPARATOR

convalescent plasma

Intervention Type BIOLOGICAL

The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

convalescent plasma

The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age = or \> than 18 years; .
* Laboratory-proven COVID-19 infection by RT-PCR in any clinical sample . Time since symptom onset less than 10 days at the time of screening; - . Presence of COVID-19 pneumonia, with a typical, indeterminate or atypical compatible image in a chest tomography exam (see definition below) -
* Presence of one of the following criteria:
* Need for\> 3L of O2 in the catheter / mask or\> 25% in the Venturi mask to maintain O2 saturation\> 92% B presence of respiratory distress syndrome with PaO2 / FiO2 \<300mmHg If intubated, within 48 hours of orotracheal intubation
* Absence of a history of serious adverse reactions to transfusion, for example, anaphylaxis; - .Participation approval by the research clinician

Exclusion Criteria

* Already enrolled in another clinical trial evaluating antiviral or immunobiological therapy for the treatment of COVID-19.
* IgA deficiency
* Presence of a clinical condition that does not allow infusion of 400 ml of volume at clinical discretion
* Pregnancy or breastfeeding
* Receipt of immunoglobulin in the last 30 days
* Presence of significant risk of death within the next 48 hours at clinical discretion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No